Outcomes After Fecal Microbiota Transplantation in Combination With Bezlotoxumab for Inflammatory Bowel Disease and Recurrent Clostridioides difficile Infection.
Am J Gastroenterol
; 119(7): 1433-1436, 2024 07 01.
Article
en En
| MEDLINE
| ID: mdl-38501667
ABSTRACT
ABSTRACT Fecal microbiota transplantation (FMT) prevents recurrent Clostridioides difficile infections (rCDI) in patients with inflammatory bowel disease. Bezlotoxumab is also indicated to prevent rCDI. We assess the impact of FMT in combination with bezlotoxumab in patients with inflammatory bowel disease and rCDI. We conducted a multicenter randomized placebo-controlled trial. All received a single colonoscopic FMT. Patients were randomized 11 to receive bezlotoxumab or placebo. Sixty-one patients were enrolled (30 received treatment and 31 received placebo). Overall, 5 participants (8%) experienced a CDI recurrence; 4 in the treatment arm, 1 in the placebo arm (13% vs 3%, P = 0.15). There was no clear benefit to the combination approach compared with FMT alone.
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Recurrencia
/
Enfermedades Inflamatorias del Intestino
/
Infecciones por Clostridium
/
Trasplante de Microbiota Fecal
/
Anticuerpos ampliamente neutralizantes
Límite:
Adult
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
Am J Gastroenterol
/
Am. j. gastroenterol. (Online)
/
The American journal of gastroenterology (Online)
Año:
2024
Tipo del documento:
Article
País de afiliación:
Estados Unidos